EUVIMEDEUVIMED entdecken
Crossref

Barnidipine as a potential alternative treatment for Raynaud's phenomenon secondary to systemic sclerosis: a retrospective pilot study

Riccardo Bixio, Francesca Mastropaolo, Matteo Appoloni, Davide Bertelle, Eugenia Bertoldo, Andrea Morciano, Stefano Di Donato, Giovanni Adami, Ombretta Viapiana, Maurizio Rossini, Idolazzi Luca

Clinical Rheumatology · 2025

DOI: 10.1007/s10067-024-07238-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Riccardo Bixio und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, Department of Medicine, University of Verona, P.le L.A. Scuro 10, 37134, Verona, Italy. riccard.bixio@univr.it. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Raynaud Disease, Nifedipine, Calcium Channel Blockers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To assess short-term barnidipine efficacy and tolerability on Systemic Sclerosis (SSc)-Raynaud's phenomenon (RP). METHODS: We retrospectively evaluated patients with SSc starting barnidipine 10 mg/day. Raynaud's Condition Score (RCS) and mean blood pressure (MBP) were assessed at baseline and 6-month follow-up. Discontinuation rates and adverse events (AEs) were compared with retrospectively evaluated patients who started MR-nifedipine 20 mg/day at our centre. RESULTS: Sixty-four patients (29 barnidipine, 35 MR-nifedipine) were evaluated. Most patients starting barnidipine had a previous CCB exposure (69%; 57.9% of these were withdrawn for AEs). During follow-up, RCS decreased significantly (6.6 ± 1.8 vs 4.4 ± 1.8, p < 0.001), while the MBP did not change significantly (86.4 ± 8.4 vs 85 ± 7.3 mmHg; p = 0.36). Nine patients (31%) discontinued barnidipine during the follow-up (AEs 6/9, inefficacy 3/9). Previous CCB failure did not predict barnidipine withdrawal (OR = 0.188 95%CI [0.02-1.8]; p = 0.147). No predictors of barnidipine withdrawal were found, and no clinical or demographic differences were found between patients withdrawing and continuing barnidipine. The 6-month retention rates of barnidipine and MR-nifedipine did not differ significantly (69 vs 80%; log-rank p = 0.23), and the two groups had a similar incidence of AEs leading to discontinuation (20.1 vs 17%; p = 0.48). CONCLUSIONS: Barnidipine could be an effective and well-tolerated therapeutic option to treat SSc-RP, even in patients previously failing other CCBs. Key Points • Calcium channel blockers (CCBs) currently represent the first-line treatment for Raynaud's phenomenon secondary to Systemic Sclerosis (SSc-RP). However, little data exists about using novel CCBs, such as barnidipine, in this condition. • This study retrospectively evaluated patients with SSc-RP treated with barnidipine to assess its short-term efficacy. To serve as a control group for tolerability, we retrospectively compared these patients with others starting modified release-nifedipine (MR-nifedipine). • In patients treated with barnidipine, we observed a significant decrease in Raynaud's condition score at the 6-month follow-up without substantial changes in mean blood pressure. • The proportion of adverse events and drug withdrawal rate between patients starting barnidipine and MR-nifedipine did not differ significantly, even in patients starting barnidipine after previously failing other CCBs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicRaynaud DiseaseNifedipineCalcium Channel BlockersDihydropyridinesHumansRetrospective StudiesFemaleMaleMiddle AgedPilot ProjectsAgedAdultBlood PressureTreatment Outcome

Stichwörter der Autor:innen

BarnidipineNifedipineRaynaud’s phenomenonSystemic sclerosis

Substanzen

NifedipineCalcium Channel BlockersDihydropyridines

Autor:innen und Institutionen

  • Rheumatology Unit, Department of Medicine, University of Verona, P.le L.A. Scuro 10, 37134, Verona, Italy. riccard.bixio@univr.it.
  • Rheumatology Unit, Department of Medicine, University of Verona, P.le L.A. Scuro 10, 37134, Verona, Italy.
  • Rheumatology Section, Department of Medicine, Azienda Sanitaria Friuli Occidentale, Pordenone, Italy.
  • Internal Medicine Unit, Department of Medicine, Mater Salutis Hospital, Legnago, Italy.
  • Faculty of Medicine and Health, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.

Zitieren

APA

Bixio, R., Mastropaolo, F., Appoloni, M., Bertelle, D., Bertoldo, E., Morciano, A., Di Donato, S., Adami, G., Viapiana, O., Rossini, M., & Luca, I. (2025). Barnidipine as a potential alternative treatment for Raynaud's phenomenon secondary to systemic sclerosis: a retrospective pilot study. Clinical Rheumatology. https://doi.org/10.1007/s10067-024-07238-2

Vancouver

Bixio R, Mastropaolo F, Appoloni M, Bertelle D, Bertoldo E, Morciano A, et al. Barnidipine as a potential alternative treatment for Raynaud's phenomenon secondary to systemic sclerosis: a retrospective pilot study. Clinical Rheumatology. 2025. doi:10.1007/s10067-024-07238-2

BibTeX
@article{Bixio2025,
  author = {Bixio, Riccardo and Mastropaolo, Francesca and Appoloni, Matteo and Bertelle, Davide and Bertoldo, Eugenia and Morciano, Andrea and Di Donato, Stefano and Adami, Giovanni and Viapiana, Ombretta and Rossini, Maurizio and Luca, Idolazzi},
  title = {Barnidipine as a potential alternative treatment for Raynaud's phenomenon secondary to systemic sclerosis: a retrospective pilot study},
  journal = {Clinical Rheumatology},
  year = {2025},
  doi = {10.1007/s10067-024-07238-2}
}
Kostenlos starten →